Sulforaphane inhibits invasion via activating ERK1/2 signaling in human glioblastoma U87MG and U373MG cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Li, Chunliu ^a   Zhou, Yan ^a   Peng, Xiaohui ^a   Du, Lianlian ^a   Tian, Hua ^a   Yang, Gaoxiang ^a   Niu, Jing ^a   Wu, Wei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD44V6 ANTIGEN; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SULFORAPHANE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; FLAVONOID; GELATINASE B; HERMES ANTIGEN; ISOTHIOCYANIC ACID DERIVATIVE; MAPK1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SULFORAFAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL INVASION; CELL MOTILITY; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANTICARCINOGENIC AGENTS; ANTIGENS, CD44; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; FLAVONOIDS; GLIOBLASTOMA; HUMANS; ISOTHIOCYANATES; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; UP-REGULATION;

EID: 84896502842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090520     Document Type: Article

References (53)

1. Bai RY, Staedtke V, Riggins GJ (2011) Molecular targeting of glioblastoma: Drug discovery and therapies. Trends Mol Med 17: 301-312.
2. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018. (Pubitemid 34286538)
3. Stupp R, Roila F (2009) Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4: 126-128.
4. Gielen PR, Aftab Q, Ma N, Chen VC, Hong X, et al. (2013) Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology 75: 539-48.
5. Chamberlain MC (2010) Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10: 1537-1544.
6. Higdon JV, Delage B, Williams DE, Dashwood RH (2007) Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 55: 224-236. (Pubitemid 46518152)
7. Zhang Y, Talalay P, Cho CG, Posner GH (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 89: 2399-2403.
8. Tomczyk J, Olejnik A (2010) [Sulforaphane-a possible agent in prevention and therapy of cancer]. Postepy Hig Med Dosw (Online) 64: 590-603.
9. Hahm ER, Chandra-Kuntal K, Desai D, Amin S, Singh SV (2012) Notch activation is dispensable for D, L-sulforaphane-mediated inhibition of human prostate cancer cell migration. PLOS ONE 7: e44957.
10. Shan Y, Zhang L, Bao Y, Li B, He C, et al. (2013) Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem 24: 1062-1069.
11. Jee HG, Lee KE, Kim JB, Shin HK, Youn YK (2011) Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro. Phytother Res 25: 1623-1628.
12. Lee YR, Noh EM, Han JH, Kim JM, Hwang BM, et al. (2013) Sulforaphane controls TPA-induced MMP-9 expression through the NF-kappaB signaling pathway, but not AP-1, in MCF-7 breast cancer cells. BMB Rep 46: 201-206.
13. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, et al. (2012) ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res 72: 365-374.
14. Lau MT, So WK, Leung PC (2013) Fibroblast growth factor 2 induces Ecadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLOS ONE 8: e59083.
15. Thomas SL, Alam R, Lemke N, Schultz LR, Gutierrez JA, et al. (2010) PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling. Neuro Oncol 12: 941-955.
16. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185.
17. Liu Z, Yu X, Shaikh ZA (2008) Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium. Toxicol Appl Pharmacol 228: 286-294.
18. Thomas W, Coen N, Faherty S, Flatharta CO, Harvey BJ (2006) Estrogen induces phospholipase A2 activation through ERK1/2 to mobilize intracellular calcium in MCF-7 cells. Steroids 71: 256-265. (Pubitemid 43208962)
19. Tong WG, Ding XZ, Talamonti MS, Bell RH, Adrian TE (2005) LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun 335: 949-956. (Pubitemid 41188287)
20. Chakraborty C, Barbin YP, Chakrabarti S, Chidiac P, Dixon SJ, et al. (2003) Endothelin-1 promotes migration and induces elevation of [Ca2+]i and phosphorylation of MAP kinase of a human extravillous trophoblast cell line. Mol Cell Endocrinol 201: 63-73. (Pubitemid 36434283)
21. Wu W, Ginsburg E, Vonderhaar BK, Walker AM (2005) S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res 65: 7509-7515. (Pubitemid 41161287)
22. Goulet AC, Chigbrow M, Frisk P, Nelson MA (2005) Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis 26: 109-117. (Pubitemid 40207705)
23. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, et al. (2011) Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S-phase arrest and apoptosis in human non-small cell lung cancer A549 cells. Eur J Pharmacol 663: 17-26.
24. Wang Z, Zhang B, Wang M, Carr BI (2003) Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK. J Biol Chem 278: 11138-11144. (Pubitemid 36792667)
25. Huang TY, Chang WC, Wang MY, Yang YR, Hsu YC (2012) Effect of sulforaphane on growth inhibition in human brain malignant glioma GBM 8401 cells by means of mitochondrial- and MEK/ERK-mediated apoptosis pathway. Cell Biochem Biophys 63: 247-259.
26. Hsu YC, Chang SJ, Wang MY, Chen YL, Huang TY (2013) Growth Inhibition and Apoptosis of Neuroblastoma Cells Through ROS-Independent MEK/ERK Activation by Sulforaphane. Cell Biochem Biophys 66(3): 765-74.
27. Li Z, Du L, Li C, Wu W (2013) Human chorionic gonadotropin beta induces cell motility via ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells. J Neurooncol 111: 237-244.
28. Li Z, Li C, Du L, Zhou Y, Wu W (2013) Human chorionic gonadotropin beta induces migration and invasion via activating ERK1/2 and MMP-2 in human prostate cancer DU145 cells. PLOS ONE 8: e54592.
29. Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792. (Pubitemid 29220691)
30. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A (2009) Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 21: 1323-1333.
31. Rao JS (2003) Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501. (Pubitemid 37328837)
32. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, et al. (2008) Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 27: 4830-4840.
33. Yang JL, Lin JH, Weng SW, Chen JC, Yang JS, et al. (2013) Crude extract of Euphorbia formosana inhibits the migration and invasion of DU145 human prostate cancer cells: The role of matrix metalloproteinase-2/9 inhibition via the MAPK signaling pathway. Mol Med Rep 7: 1403-1408.
34. Deng W, Sui H, Wang Q, He N, Duan C, et al. (2013) A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways. BMC Complement Altern Med 13: 65.
35. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, et al. (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13-24. (Pubitemid 121001209)
36. Schmidt L, Kling T, Monsefi N, Olsson M, Hansson C, et al. (2013) Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions. Neuro Oncol 15: 1469-1478.
37. Karmakar S, Weinberg MS, Banik NL, Patel SJ, Ray SK (2006) Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane. Neuroscience 141: 1265-1280. (Pubitemid 44128679)
38. Xu C, Shen G, Yuan X, Kim JH, Gopalkrishnan A, et al. (2006) ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis 27: 437-445. (Pubitemid 43372873)
39. Chen JR, Plotkin LI, Aguirre JI, Han L, Jilka RL, et al. (2005) Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie antiversus pro-apoptotic effects of estrogens. J Biol Chem 280: 4632-4638. (Pubitemid 40288632)
40. Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC, et al. (2007) Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERKdependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis 28: 977-987.
41. Damm S, Koefinger P, Stefan M, Wels C, Mehes G, et al. (2010) HGFpromoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol 130: 1893-1903.
42. Shi MD, Shih YW, Lee YS, Cheng YF, Tsai LY (2013) Suppression of 12-Otetradecanoylphorbol-13-acetate-induced MCF-7 breast adenocarcinoma cells invasion/migration by alpha-tomatine through activating PKCalpha/ERK/NFkappaB- dependent MMP-2/MMP-9 expressions. Cell Biochem Biophys 66: 161-174.
43. Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292.
44. Broussard JA, Webb DJ, Kaverina I (2008) Asymmetric focal adhesion disassembly in motile cells. Curr Opin Cell Biol 20: 85-90.
45. Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, et al. (2006) Colocalization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res 312: 1240-1253.
46. Heider KH, Kuthan H, Stehle G, Munzert G (2004) CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53: 567-579. (Pubitemid 38858330)
47. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, et al. (2000) CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci 910: 106-118; discussion 118-120.
48. Zhang XG, Lu XF, Jiao XM, Chen B, Wu JX (2012) PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Exp Ther Med 4: 1005-1009.
49. Griebling T, Palechek P, Cohen M (1997) Immunohistochemical and soluble expression of CD44 in primary and metastatic human prostate cancers. Int J Oncol 10: 697-702. (Pubitemid 27122850)
50. Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, et al. (2004) Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer 112: 121-129. (Pubitemid 39249499)
51. Hanlon N, Coldham N, Gielbert A, Kuhnert N, Sauer MJ, et al. (2008) Absolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in rat. Br J Nutr 99: 559-564. (Pubitemid 351223423)
52. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, et al. (2009) Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 58: 949-963.
53. Choi S, Singh SV (2005) Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 65: 2035-2043. (Pubitemid 40478634)